Investor Alert: Pomerantz Law Firm Investigates Ionis Pharmaceuticals for Potential Securities Fraud
Pomerantz LLP is investigating potential securities fraud or other unlawful business practices by Ionis Pharmaceuticals, Inc. (IONS) following the failure of its late-stage trial for Wainua, leading to a 23.9% drop in stock price on July 9, 2026.
Topics: class action clinical trial failure securities fraud stock price drop